Cargando…

Ex Vivo Heart Perfusion for Cardiac Transplantation Allowing for Prolonged Perfusion Time and Extension of Distance Traveled for Procurement of Donor Hearts: An Initial Experience in the United States

Scarcity of donor hearts continues to be a challenge for heart transplantation (HT). The recently Food and Drug Administration–approved Organ Care System (OCS; Heart, TransMedics) for ex vivo organ perfusion enables extension of ex situ intervals and thus may expand the donor pool. Because postappro...

Descripción completa

Detalles Bibliográficos
Autores principales: Isath, Ameesh, Ohira, Suguru, Levine, Avi, Pan, Stephen, Aggarwal-Gupta, Chhaya, Lanier, Gregg M., Wolfe, Kevin, Spielvogel, David, Gass, Alan, Kai, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949869/
https://www.ncbi.nlm.nih.gov/pubmed/36845853
http://dx.doi.org/10.1097/TXD.0000000000001455
_version_ 1784893042077990912
author Isath, Ameesh
Ohira, Suguru
Levine, Avi
Pan, Stephen
Aggarwal-Gupta, Chhaya
Lanier, Gregg M.
Wolfe, Kevin
Spielvogel, David
Gass, Alan
Kai, Masashi
author_facet Isath, Ameesh
Ohira, Suguru
Levine, Avi
Pan, Stephen
Aggarwal-Gupta, Chhaya
Lanier, Gregg M.
Wolfe, Kevin
Spielvogel, David
Gass, Alan
Kai, Masashi
author_sort Isath, Ameesh
collection PubMed
description Scarcity of donor hearts continues to be a challenge for heart transplantation (HT). The recently Food and Drug Administration–approved Organ Care System (OCS; Heart, TransMedics) for ex vivo organ perfusion enables extension of ex situ intervals and thus may expand the donor pool. Because postapproval real-world outcomes of OCS in HT are lacking, we report our initial experience. METHODS. We retrospectively reviewed consecutive patients who received HT at our institution in the post–Food and Drug Administration approval period from May 1 to October 15, 2022. Patients were divided into 2 groups: OCS versus conventional technique. Baseline characteristics and outcomes were compared. RESULTS. A total of 21 patients received HT during this period, 8 using OCS and 13 conventional techniques. All hearts were from donation after brain death donors. The indication for OCS was an expected ischemic time of >4 h. Baseline characteristics in the 2 groups were comparable. The mean distance traveled for heart recovery was significantly higher in the OCS group (OCS, 845 ± 337, versus conventional, 186 ± 188 mi; P < 0.001), as was the mean total preservation time (6.5 ± 0.7 versus 2.5 ± 0.7 h; P < 0.001). The mean OCS time was 5.1 ± 0.7 h. In-hospital survival in the OCS group was 100% compared with 92.3% in the conventional group (P = 0.32). Primary graft dysfunction was similar in both groups (OCS 12.5% versus conventional 15.4%; P = 0.85). No patient in the OCS group required venoarterial extracorporeal membrane oxygenation support after transplant compared with 1 in the conventional group (0% versus 7.7%; P = 0.32). The mean intensive care unit length of stay after transplant was comparable. CONCLUSIONS. OCS allowed utilization of donors from extended distances that otherwise would not be considered because ischemic time would be prohibitive by conventional technique.
format Online
Article
Text
id pubmed-9949869
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-99498692023-02-24 Ex Vivo Heart Perfusion for Cardiac Transplantation Allowing for Prolonged Perfusion Time and Extension of Distance Traveled for Procurement of Donor Hearts: An Initial Experience in the United States Isath, Ameesh Ohira, Suguru Levine, Avi Pan, Stephen Aggarwal-Gupta, Chhaya Lanier, Gregg M. Wolfe, Kevin Spielvogel, David Gass, Alan Kai, Masashi Transplant Direct Heart Transplantation Scarcity of donor hearts continues to be a challenge for heart transplantation (HT). The recently Food and Drug Administration–approved Organ Care System (OCS; Heart, TransMedics) for ex vivo organ perfusion enables extension of ex situ intervals and thus may expand the donor pool. Because postapproval real-world outcomes of OCS in HT are lacking, we report our initial experience. METHODS. We retrospectively reviewed consecutive patients who received HT at our institution in the post–Food and Drug Administration approval period from May 1 to October 15, 2022. Patients were divided into 2 groups: OCS versus conventional technique. Baseline characteristics and outcomes were compared. RESULTS. A total of 21 patients received HT during this period, 8 using OCS and 13 conventional techniques. All hearts were from donation after brain death donors. The indication for OCS was an expected ischemic time of >4 h. Baseline characteristics in the 2 groups were comparable. The mean distance traveled for heart recovery was significantly higher in the OCS group (OCS, 845 ± 337, versus conventional, 186 ± 188 mi; P < 0.001), as was the mean total preservation time (6.5 ± 0.7 versus 2.5 ± 0.7 h; P < 0.001). The mean OCS time was 5.1 ± 0.7 h. In-hospital survival in the OCS group was 100% compared with 92.3% in the conventional group (P = 0.32). Primary graft dysfunction was similar in both groups (OCS 12.5% versus conventional 15.4%; P = 0.85). No patient in the OCS group required venoarterial extracorporeal membrane oxygenation support after transplant compared with 1 in the conventional group (0% versus 7.7%; P = 0.32). The mean intensive care unit length of stay after transplant was comparable. CONCLUSIONS. OCS allowed utilization of donors from extended distances that otherwise would not be considered because ischemic time would be prohibitive by conventional technique. Lippincott Williams & Wilkins 2023-02-22 /pmc/articles/PMC9949869/ /pubmed/36845853 http://dx.doi.org/10.1097/TXD.0000000000001455 Text en Copyright © 2023 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Heart Transplantation
Isath, Ameesh
Ohira, Suguru
Levine, Avi
Pan, Stephen
Aggarwal-Gupta, Chhaya
Lanier, Gregg M.
Wolfe, Kevin
Spielvogel, David
Gass, Alan
Kai, Masashi
Ex Vivo Heart Perfusion for Cardiac Transplantation Allowing for Prolonged Perfusion Time and Extension of Distance Traveled for Procurement of Donor Hearts: An Initial Experience in the United States
title Ex Vivo Heart Perfusion for Cardiac Transplantation Allowing for Prolonged Perfusion Time and Extension of Distance Traveled for Procurement of Donor Hearts: An Initial Experience in the United States
title_full Ex Vivo Heart Perfusion for Cardiac Transplantation Allowing for Prolonged Perfusion Time and Extension of Distance Traveled for Procurement of Donor Hearts: An Initial Experience in the United States
title_fullStr Ex Vivo Heart Perfusion for Cardiac Transplantation Allowing for Prolonged Perfusion Time and Extension of Distance Traveled for Procurement of Donor Hearts: An Initial Experience in the United States
title_full_unstemmed Ex Vivo Heart Perfusion for Cardiac Transplantation Allowing for Prolonged Perfusion Time and Extension of Distance Traveled for Procurement of Donor Hearts: An Initial Experience in the United States
title_short Ex Vivo Heart Perfusion for Cardiac Transplantation Allowing for Prolonged Perfusion Time and Extension of Distance Traveled for Procurement of Donor Hearts: An Initial Experience in the United States
title_sort ex vivo heart perfusion for cardiac transplantation allowing for prolonged perfusion time and extension of distance traveled for procurement of donor hearts: an initial experience in the united states
topic Heart Transplantation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949869/
https://www.ncbi.nlm.nih.gov/pubmed/36845853
http://dx.doi.org/10.1097/TXD.0000000000001455
work_keys_str_mv AT isathameesh exvivoheartperfusionforcardiactransplantationallowingforprolongedperfusiontimeandextensionofdistancetraveledforprocurementofdonorheartsaninitialexperienceintheunitedstates
AT ohirasuguru exvivoheartperfusionforcardiactransplantationallowingforprolongedperfusiontimeandextensionofdistancetraveledforprocurementofdonorheartsaninitialexperienceintheunitedstates
AT levineavi exvivoheartperfusionforcardiactransplantationallowingforprolongedperfusiontimeandextensionofdistancetraveledforprocurementofdonorheartsaninitialexperienceintheunitedstates
AT panstephen exvivoheartperfusionforcardiactransplantationallowingforprolongedperfusiontimeandextensionofdistancetraveledforprocurementofdonorheartsaninitialexperienceintheunitedstates
AT aggarwalguptachhaya exvivoheartperfusionforcardiactransplantationallowingforprolongedperfusiontimeandextensionofdistancetraveledforprocurementofdonorheartsaninitialexperienceintheunitedstates
AT laniergreggm exvivoheartperfusionforcardiactransplantationallowingforprolongedperfusiontimeandextensionofdistancetraveledforprocurementofdonorheartsaninitialexperienceintheunitedstates
AT wolfekevin exvivoheartperfusionforcardiactransplantationallowingforprolongedperfusiontimeandextensionofdistancetraveledforprocurementofdonorheartsaninitialexperienceintheunitedstates
AT spielvogeldavid exvivoheartperfusionforcardiactransplantationallowingforprolongedperfusiontimeandextensionofdistancetraveledforprocurementofdonorheartsaninitialexperienceintheunitedstates
AT gassalan exvivoheartperfusionforcardiactransplantationallowingforprolongedperfusiontimeandextensionofdistancetraveledforprocurementofdonorheartsaninitialexperienceintheunitedstates
AT kaimasashi exvivoheartperfusionforcardiactransplantationallowingforprolongedperfusiontimeandextensionofdistancetraveledforprocurementofdonorheartsaninitialexperienceintheunitedstates